Dr. Jay Steven Lipshitz, MD

Dr. Lipshitz practices at Port Jefferson Station Medical Oncology in Ridge, New York.

Dr. Lipshitz's NPI, 1134363278, was assigned on April 20, 2009. Dr. Lipshitz graduated from Albert Einstein College of Medicine in 2006. Dr. Lipshitz holds New York license 250907.

Dr. Lipshitz's primary practice is Port Jefferson Station Medical Oncology, at 1 Research Rd, Ridge, NY 11961 in Suffolk County. The practice phone is (631) 751-3000.

Dr. Lipshitz's primary practice is Port Jefferson Station Medical Oncology in Ridge, New York. Dr. Lipshitz is also affiliated with Tisch Hospital. The medical group on file is New York Cancer & Blood Specialists. Dmand AI also links Dr. Lipshitz to 4 more hospitals and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lipshitz practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lipshitz's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lipshitz is board certified in hematology by the American Board of Internal Medicine. Dr. Lipshitz is licensed in New York.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and immune deficiency disease among the conditions Dr. Lipshitz treats.

CMS data shows 844 Medicare services from Dr. Lipshitz across 7 procedure codes in 2024, for 363 Medicare patients. Medicare paid $65,231 for them.

CMS counts 363 Medicare patients who saw Dr. Lipshitz in 2024. The largest group is 65 to 74, with 128 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 52% are also on Medicaid. Their average risk score is 2.24, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lipshitz's median patient age at 57, with 63% women.

In 2024, Dr. Lipshitz wrote 714 Medicare Part D claims for 133 patients. 70% of them were for generic drugs. CMS names the drug for 563 of them, across 24 drugs with 11 or more claims each, at $957,005 in total drug cost. In 2023, CMS named 377 claims across 17 drugs.

Dr. Lipshitz accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lipshitz as offering telehealth.

Dmand AI links 11 papers to Dr. Lipshitz, published from 2010 to 2021. 2011 was the busiest year, with 2. The most frequent topics are Factor V. Dr. Lipshitz has published most often in Clin Case Rep. Dr. Lipshitz's most frequent co-authors are Bernadine R. Donahue, MD, Pooja Murthy, MD and Sudhamshi Toom.

CMS Open Payments shows 298 general payments to Dr. Lipshitz from 35 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 100% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,044.

Dr. Lipshitz graduated from Albert Einstein College of Medicine in 2006.

Dr. Lipshitz is in network with 16 carriers, including Aetna, Elevance and United Healthcare. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.